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Abstract
Background: Positron emission tomography (PET) allows sensitive, non-invasive analysis of the distribution of
radiopharmaceutical tracers labeled with positron (b
+)-emitting radionuclides in small animals and humans. Upon b
+
decay, the initial velocity of high-energy b
+ particles can momentarily exceed the speed of light in tissue, producing
Cerenkov radiation that is detectable by optical imaging, but is highly absorbed in living organisms.
Principal Findings: To improve optical imaging of Cerenkov radiation in biological systems, we demonstrate that Cerenkov
radiation from decay of the PET isotopes
64Cu and
18F can be spectrally coupled by energy transfer to high Stokes-shift
quantum nanoparticles (Qtracker705) to produce highly red-shifted photonic emissions. Efficient energy transfer was not
detected with
99mTc, a predominantly c-emitting isotope. Similar to bioluminescence resonance energy transfer (BRET) and
fluorescence resonance energy transfer (FRET), herein we define the Cerenkov radiation energy transfer (CRET) ratio as the
normalized quotient of light detected within a spectral window centered on the fluorophore emission divided by light
detected within a spectral window of the Cerenkov radiation emission to quantify imaging signals. Optical images of
solutions containing Qtracker705 nanoparticles and [
18F]FDG showed CRET ratios in vitro as high as 8.861.1, while images of
mice with subcutaneous pseudotumors impregnated with Qtracker705 following intravenous injection of [
18F]FDG showed
CRET ratios in vivo as high as 3.560.3.
Conclusions: Quantitative CRET imaging may afford a variety of novel optical imaging applications and activation strategies
for PET radiopharmaceuticals and other isotopes in biomaterials, tissues and live animals.
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Introduction
Positron emission tomography (PET) allows sensitive, non-
invasive measurement of the distribution of picomolar quantities of
radiopharmaceuticals labeled with positron (b
+)-emitting radionu-
clides (e.g.,
11C,
18F,
64Cu,
68Ga) in small animals and humans [1].
Upon b
+ decay, the initial velocity of high-energy b
+ particles can
initially exceed the speed of light in tissue, thereby producing
Cerenkov radiation [2,3]. Unlike fluorescence or emission spectra
that have characteristic spectral peaks, Cerenkov radiation spectra
are continuous. The relative intensity is proportional to frequency,
and thus, for Cerenkov radiation, higher frequencies (ultraviolet/
blue) are most intense [2]. Recently, light photons attributed to
Cerenkov radiation emitted by common PET isotopes have been
detected in live mice in vivo using sensitive CCD optical imaging
systems [4,5,6]. Because the ultraviolet/blue wavelengths of
Cerenkov radiation are highly absorbed in living tissues (by water,
hemoglobin, cytochromes, etc.), modest signals and heavily
surface-weighted images as recorded by external imaging cameras
were produced. To overcome these limitations and provide
quantitative optical methods to detect b
+ decay in biological
tissues, we hypothesized that Cerenkov radiation could be
spectrally coupled by energy transfer to high Stokes-shift quantum
nanoparticles (Qtracker705) to produce highly red-shifted emission
spectra from the decay of PET isotopes compatible with biological
imaging.
Materials and Methods
Materials
Athymic nude mice (nu/nu; 6 weeks old) were purchased from
Taconic (Hudson, NY). [
18F]FDG and [
64Cu]CuCl2 were
obtained from the cyclotron facility, Washington University
School of Medicine, St. Louis, MO. [
99m Tc]NaTcO4 was
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Louis, MO). Qtracker705 quantum dots were purchased from
Invitrogen Inc. (Carlsbad, CA). Phenol-free Matrigel was pur-
chased from BD Biosciences (San Jose, CA). Clear-bottom black
96-well plates were purchased from Thermo Fisher Scientific Inc.
(Waltham, MA).
Luminescence Spectra of Cerenkov Radiation and
Quantum Dots
Emission spectra were obtained with a spectrophotometer (Cary
Eclipse; Varian Inc., Palo Alto, CA) zeroed with 500 mL of PBS in
a quartz cuvette. Then, 200 mL of PBS were removed and
replaced with 200 mLo f[
64Cu]CuCl2 (71.8 MBq; 1.94 mCi)
diluted into PBS, and wavelength scanned (20 nm emission slit
width, 10 nm interval, 10 second gate, PMT 700 mV, 6 scans).
Following baseline scanning, 12.5 mL of a stock solution of
Qtracker705 (2 mM) was added to the cuvette (final concentration,
49 nM) and mixed by pipetting. Spectra were obtained as above.
This procedure was repeated to achieve spectra for both 222 nM
and 400 nM Qtracker705 by addition of appropriate volumes of
Qtracker705 stock solution to the cuvette. Each spectrum was the
average of 6 scans. Spectra of [
99m Tc]NaTcO4 alone or in the
presence of 400 nM Qtracker 705 were performed identically.
The signal at each wavelength in a given scan was decay corrected
for time post-addition of activity to the cuvette. After obtaining
scans of [
64Cu]CuCl2 with 400 nM Qtracker705, the cuvette was
capped, sealed with parafilm, and allowed to decay until no
detectable activity remained. Spectra of the decayed sample
containing 400 nM Qtracker705 were again obtained. Spectra
were also obtained using 4.3 nM of non-radiolabeled CuCl2 in
PBS alone and in the presence of 400 nM Qtracker705 to serve as
non-radioactive controls. A fluorescence emission spectrum of the
decayed sample containing 400 nM Qtracker705 was obtained
(excitation 350 nm, 10 nm excitation and emission slit widths,
0.5 nm interval, 1 sec averaging, PMT 600 mV). For analysis,
data were plotted as RFU at a given wavelength.
Imaging CRET In Vitro
For imaging the concentration-dependence of Qtracker705
emissions, various aliquots of the 2 mM Qtracker705 stock solution
were added to PBS in a black 96-well plate (final concentrations: 0,
10, 25, 50, 100, and 200 nM). [
18F]FDG diluted in PBS was then
added to each well (5.6 MBq (150 mCi) per well at the time of
imaging). Each concentration of Qtracker705 was measured in
triplicate and the total volume was 100 mL in each well after
addition of [
18F]FDG. Plates were imaged in an IVIS 100 imaging
system (Caliper Life Sciences, Hopkinton, MA; binning 8, FOV
15, 1/f stop, 10 sec exposure). Images were captured using open,
,510 nm, 500–570 nm, and .590 nm emission filters in rapid
succession. For imaging the dose-dependence of [
18F]FDG, 2 mL
of the 2 mM Qtracker705 stock solution was added to PBS in a 96-
well plate (final concentration, 40 nM). The volume of [
18F]FDG
stock added to each well was adjusted for radioactive decay (final
doses: 0, 0.037, 0.37, 3.7, 37 MBq (0, 1, 10, 100, and 1000 mCi) at
the time of imaging). Each dose of radioactivity was measured in
triplicate and final total volume (100 mL) was titrated with PBS in
each well after addition of [
18F]FDG. Plates were imaged in the
IVIS 100 imaging system (binning 8, FOV 15, 1/f, 30 sec
exposure). Images were acquired using open, ,510 nm, 500–
570 nm, and .590 nm emission filters in rapid succession. To
prevent confounding effects from high-energy annihilation pho-
tons striking the detector chip in the camera, random outlying
pixels (‘‘hot pixels’’) were adjusted to the mean value of the nearest
neighboring pixels using ImageJ software (National Institutes of
Health, Bethesda, MD) prior to analysis. Image analysis and
photon flux measurements were determined with Living Image 3.2
and Igor Pro software (Caliper Life Sciences).
Imaging CRET In Vivo
Animal care and protocols were approved by the Washington
University Medical School Animal Studies Committee (Protocol
20090260). To generate imaging phantoms in vivo, Matrigel was
mixed with either Qtracker705 (200 nM or 500 nM final
concentration in PBS) or an equal volume of PBS in a microfuge
tube. Athymic nude mice were injected subcutaneously with
150 mL of the Matrigel-Qtracker mix on the right flank or the
Matrigel-PBS mix on the left flank, and returned to their cages for
15 minutes while the Matrigel solidified. To collect background
images, mice were imaged under 2.5% isoflurane anesthesia in an
IVIS 100 imaging system (bining 8, FOV 15, 1/f, 1 min exposure)
using open, ,510 nm, 500–570 nm, and .590 nm emission
filters in rapid succession. Mice were then injected with 100 mLo f
[
18F]FDG (17.6 MBq; 475 mCi) in PBS via tail vein and imaged
5 minutes later as above. Mice were reimaged after 30 minutes,
which allowed renal clearance of [
18F]FDG. Hot pixels that
occurred over regions of interest that contained pseudotumor
phantoms were adjusted to the mean value of the nearest
neighboring pixels using ImageJ software prior to further analysis.
Photon flux measurements and image analysis were performed
using Living Image 3.2 and Igor Pro software (Caliper Life
Sciences). Matched red-filter images were divided by blue-filter
images, and ROIs over the pseudotumors were used to calculate
tumor CRET ratios. For selected images, the mean red/blue pixel
values from a ROI over the PBS pseudotumor were subtracted
from all pixels to approximate a calculated CRET image.
Calculation of CRET Ratios
Empirically, in the presence of a fluorophore and Cerenkov
radiation, CRET can be calculated in a manner similar to BRET
[7,8] and FRET [9] as the quotient of light detected within a
spectral window (X) centered on the fluorophore emission divided
by light detected within a spectral window (Y) of the Cerenkov
radiation emission, minus the quotient of light detected in windows
X and Y in the presence of Cerenkov radiation alone (Eq. 1):
CRETx~
CerenkovzFluorophoreX
CerenkovzFluorophoreY
{
CerenkovX
CerenkovY
ð1Þ
In the case of Qtracker705, then:
CRETw590~
CerenkovzQtracker750w590
CerenkovzQtracker750v510

ave
{
Cerenkovw590
Cerenkovv510

ave
ð2Þ
Statistical Analyses
Data were reported as mean values 6 standard error of the
mean (SEM) for the number of wells or animals as indicated in
figure legends. Pairs were compared with the Student t-test [10]
and values of p#0.05 were considered significant.
Results
As a first demonstration, UV/vis emission spectra recorded
from phosphate-buffered saline (PBS) containing 70 MBq
CRET Imaging
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64Cu]CuCl2 (
64Cu: half-life, 12.7 hrs; b
+ decay, 19%,
0.655 MeV; b
2 decay, 39%, 0.578 MeV) showed a broad
maximum at 400–550 nm with a monotonic decline out to
800 nm (Figure 1A), a spectral shape attributed to the inverse
dependence of Cerenkov radiation intensity on wavelength,
modified by the wavelength-dependence of the refractive index
of water, the depth-dependence of measured spectra, and detector
characteristics [2,11,12]. [
64Cu]CuCl2 was selected for this
experiment because of its long half-life, allowing little decay over
the time needed for data collection. Addition of Qtracker705
nanoparticles, selected because their absorption spectra overlap
the UV/blue emissions of Cerenkov radiation [13], reduced
substantially the 400–550 nm broad band emissions while
producing a peak centered on 705 nm. Importantly, the new
peak was Qtracker705 concentration-dependent (49 nM to
400 nM) and corresponded to the peak emission of Qtracker705,
consistent with Cerenkov radiation energy transfer (CRET).
Furthermore, Qtracker705 solution (400 nM) scanned after
radioactive decay produced near background emissions. The
705 nm peak was not due to spontaneous non-radioactive
emission processes, such as phosphorescence, since equivalent
solutions of Qtracker705 (400 nM) in PBS with or without non-
Figure 1. Spectral analysis. (A) UV/vis emission spectra of [
64Cu]CuCl2 in PBS containing various concentrations of Qtracker705 nanoparticles
(Qdots ) demonstrate Cerenkov radiation energy transfer (CRET); (blue) [
64Cu]CuCl2 without Qdots, (green) [
64Cu]CuCl2 with 49 nM Qdots, (orange)
[
64Cu]CuCl2 with 222 nM Qdots, (red) [
64Cu]CuCl2 with 400 nM Qdots, (black) non-radioactive CuCl2 without Qdots, (brown) non-radioactive CuCl2
with 400 nM Qdots, (gray) decayed [
64Cu]CuCl2 with 400 nM Qdots. (B) Fluorescence emission spectrum (350 nm excitation) of decayed (.8 half-
lives) [
64Cu]CuCl2 in PBS containing 400 nM Qtracker705. (C) UV/vis emission spectra of [
99mTc]NaTcO4 in PBS without (black) and with (red) 400 nM
Qtracker705 nanoparticles.
doi:10.1371/journal.pone.0013300.g001
CRET Imaging
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emissions. Qtracker705 nanoparticles were stable; after complete
radioactive decay, control fluorescence emission spectra of the
nanoparticles were unchanged (350 nm excitation; 705 nm peak
emission) (Figure 1B) .T h ep e a kc e n t e r e do n7 0 5n mc o u l dn o tb e
attributed to c radiation at these concentrations since Qtracker705
solution (400 nM) spiked with [
99mTc]NaTcO4 (
99mTc: half-life,
6.0 hrs; c decay, 89%, 0.140 MeV), a predominantly c-emitting
isotope, yielded a flat emission spectra superimposable on PBS alone
spiked with [
99mTc]NaTcO4 (Figure 1C).
Using 96-well plates, we then imaged Qtracker705 nanoparti-
cles mixed at several different concentrations in PBS with
5.6 MBq (150 mCi) of [
18F]fluorodeoxyglucose (FDG) (
18F: half-
life, 1.83 hrs; b
+ decay, 97%, 0.635 MeV). Images were captured
with an IVIS 100 system using open, ,510 nm, 500–570 nm, and
.590 nm filters in rapid succession to distinguish the bulk of the
Cerenkov radiation (,510 nm) from radiation energy transfer to
the Qtracker705 nanoparticles (.590 nm) (Figure 2A). The
photon flux in the red filtered images (.590 nm) increased with
increasing concentration of Qtracker705, while the blue filtered
images (,510 nm) decreased slightly, consistent with absorption of
Cerenkov radiation (Figure 2B). We propose use of equation Eq.
1 (Methods) to quantify CRET by calculation of a CRET ratio. As
applied herein, CRET ratios were calculated using Eq. 2 and, at
constant [
18F]FDG, found to correlate with the concentration of
Qtracker705 (Figure 2C). Similarly, at constant Qtracker705
concentration (40 nM), CRET ratios correlated with the amount
of [
18F]FDG radioactivity added to the solution (Figure 3).
Obscuring the plate with a single sheet of black paper completely
blocked CRET signals, confirming that the events detected in the
IVIS 100 were visible light photons, not high-energy radioactivity
(data not shown). CRET ratios in vitro as high as 8.161.1 (n=3)
were observed.
Because red-shifted emissions penetrate biological tissues more
readily than blue emissions [14], CRET may enhance optical
imaging of PET radiopharmaceuticals in living animals. As proof-
of-principle, we embedded Qtracker705 nanoparticles or vehicle
(PBS) alone in Matrigel solutions and established identical
subcutaneous implants on opposing flanks of nude (nu/nu) mice
[15] for live animal imaging (Figure 4A). We embedded two
different concentrations of Qtracker705 (200 nM and 500 nM) in
two different cohorts of mice and imaged at 5 minutes and
30 minutes following tail-vein injection of [
18F]FDG (17.6 MBq;
475 mCi). Five minutes post [
18F]FDG injection, red/blue image
ratios (signal in the .590 nm filtered (red) images divided by the
,510 nm (blue) images) for 200 nM Qtracker705-impregnated
Matrigel pseudotumors were significantly higher than PBS-
containing pseudotumors (5.160.2 (n=4) versus 3.160.2, respec-
tively; p,0.0001). The corresponding CRET ratio was 2.160.2 in
vivo (Table 1). Thirty minutes post-injection, Qtracker705-
containing pseudotumors had red/blue ratios of 4.860.1 and
PBS-containing pseudotumors had red/blue ratios of 3.060.2,
yielding a CRET ratio of 1.860.2 (Table 1; Figure 4B). By
comparison, 5 minutes post [
18F]FDG injection, 500 nM
Qtracker705-impregnated Matrigel pseudotumors had red/blue
ratios of 5.560.4 (n=3) and PBS-containing pseudotumors had
Figure 2. CRET in vitro was dependent on Qtracker705 nanoparticle concentration. (A) IVIS 100 images of 96-well assay plates using either
a ,510 nm filter (left) or a .590 nm filter (right). Note the red ‘‘hot pixel’’ from an annihilation event detected by the CCD camera in one image (left),
and the presence of minimally detectable CRET emitted from the wells containing 200 nM Qtracker705, but no [
18F]FDG, due to contaminating
radioactive emissions from adjacent wells (right). Qtracker705 nanoparticles show no CRET when imaged in isolation in the absence of [
18F]FDG. (B)
Plot of photon flux from either the ,510 nm filter (%) or the .590 filter (&) with increasing concentrations of Qtracker705 nanoparticles. (C) Plot of
CRET ratios versus concentration of Qtracker705 nanoparticles (dashed line is a linear fit of the data: y=0.036x+1.3; R
2=0.897).
doi:10.1371/journal.pone.0013300.g002
CRET Imaging
PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13300ratios of 2.060.6, corresponding to a CRET ratio of 3.560.3
(Table 1). Thirty minutes post-injection, 500 nM Qtracker705-
containing pseudotumors had red/blue ratios of 4.860.6 and
PBS-containing pseudotumors had a ratio of 2.660.3, yielding a
CRET ratio of 2.260.3. Cerenkov radiation spectra are
continuous, and low level emissions were evident into the far red
spectral tail (Figure 1A). Thus, areas of known high focal uptake
and excretion of [
18F]FDG (brain, heart, bladder) showed
evidence of low level Cerenkov radiation visible with the
.590 nm filter (Figure 4A, .590 filtered image).
Figure 3. CRET in vitro was dependent on [
18F]FDG radioactivity. (A) IVIS 100 images of 96-well assay plates using either a ,510 nm filter
(left) or a .590 nm filter (right). (B) Plot of photon flux from either the ,510 nm filter (%) or the .590 filter (&) with increasing amounts of [
18F]FDG
radioactivity. (C) Plot of CRET ratios versus [
18F]FDG radioactivity.
doi:10.1371/journal.pone.0013300.g003
Figure 4. CRET imaging of pseudotumor phantoms in live animals in vivo. (A) Subcutaneous pseudotumors of 500 nM Qtracker705-
impregnated Matrigel (closed arrow) and PBS-impregnated Matrigel (open arrow) in opposing flanks of nu/nu mice were imaged with an IVIS 100
using open, ,510 nm (blue), 500–570 nm (green), and .590 nm (red) filters 30 minutes following tail-vein injection of [
18F]FDG (17.6 MBq; 475 mCi).
(B) The calculated CRET image.
doi:10.1371/journal.pone.0013300.g004
CRET Imaging
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We describe a method for enhancing optical detection of PET
isotopes in biological systems, termed Cerenkov radiation energy
transfer (CRET). Similar in principle to BRET [7] and FRET [9],
Cerenkov radiation generated by decay of a PET isotope serves as
the energy donor and a fluorophore constitutes the energy
acceptor. We propose that, in the presence of a fluorophore and
Cerenkov radiation, CRET ratios can be calculated as the ratio of
light detected within a spectral window centered on the
fluorophore emission over light detected within a spectral window
of the Cerenkov radiation emission, minus the ratio of light
detected in the same filters in the presence of Cerenkov radiation
alone (Eq. 1). As proof of principle, we quantified CRET ratios by
imaging the energy transfer of Cerenkov radiation generated from
PET isotopes to Qtracker705 nanoparticles both in vitro and in vivo.
Spectra obtained with Qtracker705 in the presence of
64Cu
showed an apparent maximum for the energy donor from 400–
550 nm for Cerenkov radiation (attributed to inverse wavelength-,
refractive index-, depth- and detector-dependent characteristics)
and a new acceptor peak centered on 705 nm corresponding to
the emission of Qtracker705, consistent with Cerenkov radiation
energy transfer. Additionally, we observed with increasing
concentrations of Qtracker705 a concomitant decrease in the
donor intensity. Such a loss, concordant with formation of the
acceptor spectral peak, is similarly observed in FRET. Further-
more, Cerenkov radiation arises from high-energy particles
traveling through a medium, inducing transient dipole-moments,
while the mechanism of non-radiative (resonance) energy transfer
with FRET involves dipole-dipole coupling. However, attributing
resonance processes to the CRET phenomena awaits specific
mechanistic studies aimed at understanding all possible energy
contributions made by decaying PET isotopes in such energy
transfer contexts.
Studies in vitro were performed by determining the concentra-
tion-dependence of Qtracker705 in the presence of a constant
amount of [
18F]FDG. We chose nanoparticle concentrations in the
nanomolar range, comparable to concentrations that would be
feasible in vivo. Within the narrow concentration range of these
experiments, we found a quasi-linear increase in CRET with
increasing concentrations of Qtracker705. This trend was
expected given the sub-optimal excitation that occurs when using
such a low-level light source compared to the high molar
absorptivity of quantum dot nanoparticles. Additionally, we
examined the dose-dependence of [
18F]FDG in the presence of
a constant amount of Qtracker705. The doses of radiation used in
this experiment also were chosen in consideration of applications
in vivo, but were limited by high-energy annihilation photons
interfering with the CCD detector. We found that CRET ratios
increased with radiation dose over the range of doses examined.
Note that the CRET ratio will depend quantitatively on the
choice of filters, isotope and fluorophore. Further refinement of
CRET imaging is anticipated as optimal filter combinations for
various isotopes and fluorophores are discovered and character-
ized. In this regard, the data in Figure 1A suggest the presence of
an isosbestic point at ,680 nm in the CRET spectra of
Qtracker705 nanoparticles. Use of narrow bandpass filter sets
that include isosbestic points may also enhance quantitative
analysis, system calibration, and depth resolution in a variety of
experimental conditions that will be explored in the future.
We have demonstrated the imaging applicability of CRET in
vivo using Matrigel pseudotumor phantoms embedded with
Qtracker705 or PBS. Following tail-vein injection of [
18F]FDG,
we were able to correctly observe the location of Qtracker-loaded
pseudotumors as early as five minutes post-injection, a time when
[
18F]FDG is widely distributed throughout the blood pool and
extracellular spaces. The mean range of positrons emitted by
18F
and
64Cu is ,0.9 mm (and for very high-energy positron emitters
such as
82Rb is ,7 mm) [16]. Thus, [
18F]FDG, in this case the
ultimate source of Cerenkov radiation, did not need to be in direct
proximity with the nanoparticles to provide adequate energy for
CRET, a potential advantage for CRET over FRET or BRET for
selected applications. For this reason, there was no need for vessel
growth within the pseudotumor for visualization by CRET.
Imaging again at 30 minutes post-injection of [
18F]FDG resulted
in reduced signal, as would be expected as [
18F]FDG cleared from
the blood pool and surface tissues. Conversely, for nanoparticles
contained within a vascularized tumor, retention of
18F]FDG
within the tumor cells would provide enhanced proximity and
delayed clearance compared to an extracellular source as
illustrated in this study. Indeed, the relationship between distance
and signal could be quite complex and will need further
characterization as CRET imaging is refined. The experiment
also was performed using either 200 nM or 500 nM Qtracker705
and, appropriately, the higher concentration yielded a higher
CRET ratio, but did not track linearly with the concentration of
Qtracker705 in vivo, as was observed in vitro. This was likely
because of non-linear tissue attenuation of photons in living
animals.
As this manuscript was submitted, a report demonstrating the
use of low-energy light from c-emitting
131I to excite quantum dot
nanoparticles in Matrigel phantoms was published independently
[17], but with some notable differences. First, in Liu et al. [17],
radiotracer was directly admixed into the Matrigel phantoms,
rather than injected systemically as in the present study, thereby
nominally concentrating the activity by ,3,000-fold (volume of
distribution: 26262m m
3 pseudotumor=8 mm
3 versus a 25 gm
mouse=25610
3 mm
3). This favorably allowed use of less
radiotracer and quantum nanoparticle material, while reducing
background signal, but did not mimic the manner in which this
technique would likely be utilized in vivo. Additionally,
131I was
chosen as the energy donor, which produced emissions dominated
by both c-rays and b
2 particles, whereas use of
18F in the present
study, a nearly pure positron emitter, formally confirmed b
+
particles as the energy donors and left little ambiguity as to the
source of the donor Cerenkov radiation observed. Last, herein we
introduce a method for quantitative analysis of the energy transfer
process by defining the CRET ratio.
Several optical imaging studies report using Cerenkov radiation
as a means of imaging tumors [4,6,17], including a recent
description of Cerenkov luminescence tomography [18]. While the
authors were able to correctly identify tumors using this method,
by comparison to traditional PET imaging, Cerenkov lumines-
cence imaging alone resulted in substantially lower spatial
resolution. This was likely a consequence of the models used for
image reconstruction and photonic limitations. Such reconstruc-
tions depend on the ability to accurately model photon
Table 1. CRET ratios of pseudotumors in vivo.
[Qtracker705] Time Post [
18F]FDG injection
5 min 30 min
200 nM 2.160.2 1.860.2
500 nM 3.560.3 2.260.3
doi:10.1371/journal.pone.0013300.t001
CRET Imaging
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sions of Cerenkov radiation are highly absorbed in tissues,
resulting in relatively short mean pathlengths for these purposes.
Thus, one way to overcome the problem of optical diffusion may
be to spectrally couple, by energy transfer, the Cerenkov radiation
to far-red and near infrared emitting quantum nanoparticles or
fluorophores.
While we focus on Cerenkov radiation from b
+ particles as the
source of excitation energy in this report, in principle, the method
should apply to any isotope that emits charged particles that
exceed the energy threshold required for Cerenkov radiation in
the media (264 keV in water). Thus, b
2 particles and a-particles of
sufficient energy [6] should also enable CRET. It is also possible
that other sources of high-energy radiation, such as Bremsstrah-
lung, radioluminescence from c-rays, and non-radiative (reso-
nance) energy transfer may also enable energy transfer and the
detection of ‘‘CRET-like’’ images. As such, further mechanistic
and chemical studies are warranted with other fluorophores and
small molecules to determine their relative contributions, strength
of signal, and tissue depth-dependence. Quantitative CRET
imaging may afford a variety of novel optical imaging applications
and activation strategies for studies of PET and other radiophar-
maceuticals as well as radiobiology in biomaterials, tissues and live
animals.
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